ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Osteosarcoma (OS) is an aggressive bone cancer with poor outcomes, especially in recurrent or metastatic cases.
• Current immunotherapies for OS show limited efficacy due to tumor heterogeneity and target protein expression variability.

Purpose of the Study:

• To investigate the potential of chimeric antigen receptor (CAR) T-cells targeting a specific isoform of alkaline phosphatase, ALPL-1, for osteosarcoma treatment.
• To evaluate the efficacy and safety of ALPL-1-targeted CAR T-cells in preclinical osteosarcoma models.

Main Methods:

• Development of a second-generation CAR construct utilizing antibodies specific to OS.
• Transduction of T-cells with the CAR construct targeting ALPL-1.
• In vitro cytotoxicity assays against ALPL-positive OS cells.
• In vivo studies using orthotopic models of primary and metastatic OS.

Main Results:

• CAR T-cells efficiently and specifically targeted ALPL-1, which is highly expressed in primary and metastatic OS.
• Demonstrated effective cytotoxicity against ALPL-positive OS cells in vitro.
• Showed significant efficacy in preclinical orthotopic OS models without observed off-target toxicities.

Conclusions:

• ALPL-1-targeted CAR T-cells represent a promising and specific therapeutic strategy for osteosarcoma.
• These findings support the clinical translation of ALPL-1-targeted CAR T-cell therapy for osteosarcoma patients.